Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
JDR Clin Trans Res ; 9(1): 72-84, 2024 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-36680313

RESUMEN

BACKGROUND: With addiction rates and opioid deaths increasing, health care providers are obligated to help stem the opioid crisis. As limited studies examine the comparative effectiveness of fixed-dose combination nonopioid analgesia to opioid-containing analgesia, a comparative effectiveness study was planned and refined by conducting a pilot study. METHODS: The Opioid Analgesic Reduction Study (OARS) pilot, a stratified, randomized, multisite, double-blind clinical trial, was designed to test technology and procedures to be used in the full OARS trial. Participants engaged in the full protocol, enabling the collection of OARS outcome data. Eligible participants reporting to 1 of 5 sites for partial or full bony impacted mandibular third molar extraction were stratified by biologic sex and randomized to 1 of 2 treatment groups, OPIOID or NONOPIOID. OPIOID participants were provided 20 doses of hydrocodone 5 mg/acetaminophen 300 mg. NONOPIOID participants were provided 20 doses of ibuprofen 400 mg/acetaminophen 500 mg. OARS outcomes data, including pain experience, adverse effects, sleep quality, pain interference, overall satisfaction, and remaining opioid tablets available for diversion, were collected via surveys, electronic medication bottles, eDiary, and activity/sleep monitor. RESULTS: Fifty-three participants were randomized with 50 completing the OARS pilot protocol. Across all outcome pain domains, in all but 1 time period, NONOPIOID was better in managing pain than OPIOID (P < 0.05 level). Other outcomes suggest less pain interference, less adverse events, better sleep quality, better overall satisfaction, and fewer opioid-containing tablets available for diversion. DISCUSSION: Results suggest patients requiring impacted mandibular third molar extraction would benefit from fixed-dose combination nonopioid analgesia. KNOWLEDGE TRANSFER STATEMENT: Study results suggest fixed-dose nonopioid combination ibuprofen 400 mg/acetaminophen 500 mg is superior to opioid-containing analgesic (hydrocodone 5 mg/acetaminophen 500 mg). This knowledge should inform surgeons and patients in the selection of postsurgical analgesia.


Asunto(s)
Analgésicos no Narcóticos , Analgésicos Opioides , Humanos , Analgésicos Opioides/uso terapéutico , Analgésicos Opioides/efectos adversos , Acetaminofén/uso terapéutico , Acetaminofén/efectos adversos , Ibuprofeno/uso terapéutico , Ibuprofeno/efectos adversos , Hidrocodona/efectos adversos , Proyectos Piloto , Combinación de Medicamentos , Analgésicos no Narcóticos/uso terapéutico , Analgésicos no Narcóticos/efectos adversos , Dolor/inducido químicamente , Dolor/tratamiento farmacológico , Método Doble Ciego
2.
J Appl Microbiol ; 120(3): 607-18, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26910858

RESUMEN

AIMS: To identify the taxonomy of tobacco rhizosphere-isolated strain Lyc2 and investigate the mechanisms of the antifungal activities, focusing on antimicrobials gene clusters identification and function analysis. METHODS AND RESULTS: Multilocus sequence typing and 16S rRNA analyses indicated that strain Lyc2 belongs to Burkholderia pyrrocinia. Bioassay results indicated strain Lyc2 showed significant antifungal activities against a broad range of plant and animal fungal pathogens and control efficacy on seedling damping off disease of cotton. A 55·2-kb gene cluster which was homologous to ocf gene clusters in Burkholderia contaminans MS14 was confirmed to be responsible for antifungal activities by random mutagenesis; HPLC was used to verify the production of antifungal compounds. Multiple antibiotic and secondary metabolized biosynthesis gene clusters predicated by antiSMASH revealed the broad spectrum of antimicrobials activities of the strain. CONCLUSIONS: Our results revealed the mechanisms of antifungal activities of strain Lyc2 and expand our knowledge about production of occidiofungin in the bacteria Burkholderia. SIGNIFICANCE AND IMPACT OF THE STUDY: Understanding the mechanisms of antifungal activities of strain Lyc2 has contributed to discovery of new antibiotics and expand our knowledge of production of occidiofungin in the bacteria Burkholderia.


Asunto(s)
Antifúngicos/farmacología , Burkholderia/metabolismo , Glicopéptidos/farmacología , Péptidos Cíclicos/farmacología , Antifúngicos/metabolismo , Burkholderia/química , Burkholderia/genética , Burkholderia/aislamiento & purificación , Hongos/efectos de los fármacos , Glicopéptidos/metabolismo , Familia de Multigenes , Péptidos Cíclicos/metabolismo , ARN Ribosómico 16S/genética , Microbiología del Suelo
3.
Int J Clin Pract ; 63(3): 360-7, 2009 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19222622

RESUMEN

BACKGROUND: Lower rates of smoking cessation and higher rates of lung cancer in African American (AA) smokers may be linked to their preference for mentholated cigarettes. AIM: This study assessed the relationship between menthol smoking, race/ethnicity and smoking cessation among a diverse cohort of 1688 patients attending a specialist smoking cessation service. RESULTS: 46% of the patients smoked mentholated cigarettes, but significantly more AA (81%) and Latino (66%) patients than Whites (32%) smoked menthols. AA and Latino menthol smokers smoked significantly fewer cigarettes per day (CPD) than non-menthol smokers (15.7 vs. 20.3, for AA, and 17.0 vs. 22.1, for Latinos), with no differences among White menthol and non-menthol smokers. At 4-week follow up, AA, Latino and White non-menthol smokers had similar quit rates (54%, 50% and 50% respectively). In contrast, among menthol smokers, AAs and Latinos had lower quit rates (30% and 23% respectively) compared with Whites (43%, p < 0.001). AA and Latino menthol smokers had significantly lower odds of quitting [odds ratio (OR) = 0.34; 95% CI = 0.17, 0.69 for AA, and OR = 0.32; 95% CI = 0.16, 0.62 for Latinos] than their non-menthol counterparts. At 6-month follow up, a similar trend was observed for the race/ethnicity subgroups, with AA menthol smokers having half the odds of being abstinent compared with AA non-menthol smokers (OR = 0.48; 95% CI = 0.25, 0.9). CONCLUSIONS: Despite smoking fewer CPD, AA and Latino menthol smokers experience reduced success in quitting as compared with non-menthol smokers within the same ethnic/racial groups.


Asunto(s)
Negro o Afroamericano/estadística & datos numéricos , Hispánicos o Latinos/estadística & datos numéricos , Cese del Hábito de Fumar/etnología , Prevención del Hábito de Fumar , Adulto , Estudios de Cohortes , Escolaridad , Femenino , Humanos , Masculino , Mentol , New Jersey , Estudios Retrospectivos , Fumar/etnología , Cese del Hábito de Fumar/estadística & datos numéricos , Factores Socioeconómicos , Resultado del Tratamiento , Población Blanca/estadística & datos numéricos
4.
Neuropediatrics ; 31(5): 227-39, 2000 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-11204280

RESUMEN

The phenotypic expression of X-linked adrenoleukodystrophy (X-ALD) ranges from the rapidly progressive childhood cerebral form to the milder adrenomyeloneuropathy (AMN) in adults. It is not possible to predict phenotype by mutation analysis or biochemical assays. This study reports on 372 patients ranging in age from less than 3 years to adulthood, who have been followed at the Kennedy Krieger Institute. With the aim of determining whether a method could be developed to predict clinical course by analysis of data available at time of first contact, the patients were subdivided into 18 subgroups on the basis of age and the extent of brain magnetic resonance (MRI) abnormality utilizing the MRI scoring system devised by Loes et al. Scores to grade degree of neurologic and neuropsychologic impairment were also developed. There was strong correlation between MRI and the neurology and neuropsychology scores at baseline. Information based exclusively on age and MRI score at time of first contact was highly predictive of future clinical course and should aid the evaluation of the effects of bone marrow transplantation and the selection of patients for this procedure, as well as the evaluation of other therapies that may be developed in the future.


Asunto(s)
Adrenoleucodistrofia/diagnóstico , Adrenoleucodistrofia/terapia , Trasplante de Médula Ósea , Encéfalo/anomalías , Ácidos Erucicos/uso terapéutico , Imagen por Resonancia Magnética , Fenotipo , Trioleína/uso terapéutico , Adrenoleucodistrofia/genética , Adrenoleucodistrofia/patología , Adulto , Factores de Edad , Edad de Inicio , Trasplante de Médula Ósea/estadística & datos numéricos , Niño , Diagnóstico Diferencial , Combinación de Medicamentos , Femenino , Estudios de Seguimiento , Genotipo , Humanos , Recién Nacido , Imagen por Resonancia Magnética/métodos , Masculino , Pronóstico , Estudios Prospectivos , Factores Sexuales , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA